Tag: massachusetts

  • Home
  • Tag: massachusetts
Top 12 Movies About Whistleblowers: Lessons for the Brave & Courageous

Top 12 Movies About Whistleblowers: Lessons for All

Top 12 Movies About Whistleblowers Whistleblowers are individuals who, despite the risk of retaliation, speak up against illegal, immoral, or unethical practices. Whistleblowers are often criticized, discriminated against, and even subjected to harassment or physical violence. To celebrate their courage and highlight the importance of their work, we have compiled a list of top 12...
Read More
Close up of books - False Claims Act and whistleblower immunity

Update on Whistleblower Immunity in DTSA of 2016

DTSA and Whistleblower Immunity Last year, we applauded the carve-out for whistleblowers in the Defend Trade Secrets Act of 2016 (DTSA). However, a recent opinion of a U.S. District Court in the First Circuit undermined the protections afforded whistleblowers under the law. Instead of receiving whistleblower immunity from the lawsuit, it became a sword to...
Read More
Cornice of old national bank, representing Deutsche Bank and whistleblowers

DuPont’s Alleged Failure to Report Health & Environmental Issues

A whistleblower lawsuit filed under the False Claims Act accuses DuPont of failing to report a chemical leak of cancer-causing gas from a plant in Louisiana, according to The Times-Picayune. The Toxic Substances Control Act requires manufacturers, processors and distributors of chemical substances to report when a substance poses a substantial risk of injury to health...
Read More
Dollar banknote on white table, representing whistleblower amendments, insider trading, and whistleblower awards.

Caremark False Claims Act Case Settles for $4.25 Million

$4.25 Million for Caremark False Claims Act Case Yesterday the U.S. Department of Justice (“DOJ”) announced an agreement with Caremark, LLC to settle allegations filed that it defrauded the federal government and five states.  Caremark, LLC is a pharmacy benefit management company (“PBM”), operated by CVS Caremark, Corp. a company which is no stranger to...
Read More
Assortment of pills in news article at Young Law Group website. Also representing REMS

Drug Quality and Security Act May Not Go Far Enough

On Monday November 18, 2013, the U.S. Senate passed a bill, by voice-vote, which had earlier cleared the House, moving the legislation on to President Obama’s desk.  H.B. 3204 the Drug Quality and Security Act (“DQSA”) passed with bipartisan support, a rare occurrence of late.  The DQSA creates a national system which will track the...
Read More
Boston at Night - U.S. District Court for the District of Massachusetts Refuses to Adopt Narrow Definition of SEC Whistleblower Under Dodd-Frank

Massachusetts Court Rejects Narrow SEC Whistleblower Definition

U.S. District Court for the District of Massachusetts Refuses to Adopt Narrow Definition of SEC Whistleblower Under Dodd-Frank On October 16, 2013, a federal court in Massachusetts issued a ruling widely applauded by whistleblower attorneys and advocates.  See Ellington v. Giacoumakis, No. 13-11791-RGS, 2013 WL 5631046 (D. Mass. Oct. 16, 2013).  The primary issue in the decision...
Read More
100 Dollar Bills representing settlement and False Claims Act

Whistleblower Rewarded $9.2M for Exposing Fraud Scheme

Whistleblower Paid $9,243,251 For Exposing False Claims Scheme On June 7, 2012, the Department of Justice reported that it had recovered $34,234,263 from Orthofix Inc., a Texas-based manufacturer of medical devices, to settle allegations under the civil False Claims Act relating to the company’s sale of bone growth stimulator devices. The Justice Department awarded whistleblower Jeffrey Bierman $9,243,251...
Read More
Assortment of pills in news article at Young Law Group website. Also representing REMS

Drug Firm Settles $3 Billion Illegal Medicare Marketing Case

On Thursday November 3, 2011, the drug firm GlaxoSmithKline finally agreed to pay a $3 billion settlement to the United States government over allegations that the company continued to practice illegal marketing tactics for their diabetes drug Avandia, which was recently restricted due to the risks it posed to the heart. According to whistleblowers within...
Read More